Catapres-tts-2 Patch
Product Images NDC 82089-202

Product Visual Gallery

This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Catapres-tts-2 (NDC 82089-202). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Technomed Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton-0.1 mg (Catapres Tts 1 Carton)

Packaging label for Catapres-TTS-1 clonidine transdermal system patch by Technomed Inc. It contains 4 systems and 4 adhesive covers with a programmed delivery of 0.1 mg clonidine per day for one week. The label includes usage and MRI safety instructions and a barcode with NDC 82089-201-34.*

FDA Label Image

Pouch(front) (0.1 mg)

Label for Catapres-TTS-1 clonidine transdermal system patch. It indicates programmed delivery of 0.1 mg clonidine per day for one week. Warnings include removal before MRI to avoid burns. The label includes expiration and lot number placeholders and is marked Rx only.*

FDA Label Image

Pouch(back) (0.1 mg)

Label on a pouch for Catapres-TTS-2 clonidine transdermal system patch. It states the pouch contains one system with medication and instructs to remove the clear backing before use. Storage instructions specify 20°C to 25°C (68°F to 77°F). Manufactured by Corium Innovations, Inc., with trademark and license information for Catapres-TTS by Technomed Inc.*

FDA Label Image

Carton-0.2 mg (Catapres Tts 2 Carton)

Packaging label for Catapres-TTS-2 clonidine transdermal system patch by Technomed Inc. The label indicates 4 systems and 4 adhesive covers delivering 0.2 mg clonidine per day for one week. Label mentions prescription use and transdermal route, with NDC 82089-202-34 visible on the carton.*

FDA Label Image

Pouch(front) (0.2 mg)

Catapres-TTS-2 (clonidine transdermal system) patch label indicating it is a programmed delivery system releasing 0.2 mg clonidine per day for one week. The label includes safety information about removing the patch before MRI procedures and notes this is an Rx only product from Technomed Inc. The expiration and lot number blocks are also visible beside the main label.*

FDA Label Image

Pouch(back) (0.2 mg)

Packaging label for Catapres-TTS-2 clonidine transdermal system patch. The label includes instructions for removing the system from the pouch, storage conditions specifying 20° to 25°C (68° to 77°F), and notes that the product is manufactured by Corium Innovations, Inc. and labeled by Technomed Inc. The label identifies the product as containing one system with medication in a sealed pouch.*

FDA Label Image

Carton-0.3 mg (Catapres Tts 3 Carton)

Catapres-TTS-3 transdermal patch, a clonidine transdermal system in .3 mg/d strength. The packaging design shows a box labeled for 4 systems and 4 adhesive covers. It specifies programmed delivery of 0.3 mg clonidine per day for one week. The labeler is Technomed Inc., and it includes instructions for transdermal use and a barcode.*

FDA Label Image

Pouch(front)- 0.3 mg (Catapres Tts 3 Pouch)

Catapres-TTS-3 transdermal patch label for clonidine transdermal system, indicating a programmed delivery of 0.3 mg clonidine per day for one week. The label includes a note about a new appearance, instructions to remove the patch before MRI procedures to avoid burns, and states it is Rx only. The labeler is Technomed Inc.*

FDA Label Image

Pouch(back)- 0.3 mg (Catapres Tts 3 Pouchb)

Label panel for Catapres-TTS-2 clonidine transdermal system patch, showing instructions to tear and remove the system from the pouch. It includes a barcode, storage conditions (20°C to 25°C or 68°F to 77°F), manufacturer information (Corium Innovations, Inc.), and trademark details for Catapres-TTS by Boehringer Ingelheim International GmbH. The label is marked with Technomed Inc. and the year 2021.*

FDA Label Image

Clonidine-structure (Clonidine Structure)

Chemical structure of clonidine, the active ingredient in Catapres-TTS-2 transdermal system. The diagram depicts the molecular arrangement including chlorine atoms and functional groups characteristic of clonidine.*

FDA Label Image

Cover (0.1 mg)

This text panel provides a warning that the adhesive cover included does not contain active medication and should be applied over the patch if necessary. It advises referring to the patient information sheet for suggestions on how to use the adhesive cover.*

FDA Label Image

Cover-0.2 mg (Cover 2)

Text panel stating that the contents include one adhesive cover and warning that it does not contain active medication. It advises to apply it over the patch if necessary and refers to patient information sheet for use suggestions.*

FDA Label Image

Cover-0.3 mg (Cover 3)

Label panel for Catapres-TTS-2 clonidine transdermal system patch indicating the contents include one adhesive cover. It includes a warning that the adhesive cover does not contain active medication and should be applied over the patch if necessary. Additional usage suggestions are referenced in the patient information sheet.*

FDA Label Image

Figure_1 (Figure 1)

An instructional diagram showing the application site for the Catapres-TTS-2 clonidine transdermal patch. It depicts the patch placement on the upper arm and the adhesive cover to be applied over the patch if necessary.*

FDA Label Image

Figure_2 (Figure 2)

The image shows the front and back of the Catapres-TTS-1 clonidine transdermal system patch packaging. The front label displays the product name Catapres-TTS-1 and indicates it contains a clonidine patch. The back label includes a warning that this cover does not contain active medication and instructions to apply it over the patch if the system becomes loose. The labeler is Technomed Inc.*

FDA Label Image

Figure_3 (Figure 3)

An instructional illustration demonstrating the application of a Catapres-TTS-2 clonidine transdermal system patch to the skin. The image shows a hand peeling the patch from its protective backing, indicating how to properly handle the transdermal patch for use.*

FDA Label Image

Figure_4 (Figure 4)

An instructional illustration showing hands applying a Catapres-TTS-2 clonidine transdermal system patch. The image demonstrates the removal of the patch backing as part of the application process for the transdermal patch.*

FDA Label Image

Figure_5 (Figure 5)

An instructional illustration showing the application of a transdermal patch on the upper arm. The image depicts a hand positioning the patch onto the skin, demonstrating correct placement for a transdermal drug delivery system.*

FDA Label Image

Figure_6 (Figure 6)

The image shows a Catapres-TTS-2 clonidine transdermal system patch with its adhesive cover. The cover includes a warning stating it does not contain active medication and should be applied over the patch if necessary, with suggestions for use found in the patient information sheet. The patch is round and designed for transdermal administration.*

FDA Label Image

System-cross-section (System Cross Section)

An instructional diagram depicting the layered structure of the Catapres-TTS-2 clonidine transdermal patch. The layers from top to bottom are labeled as Backing, Drug Reservoir, Control Membrane, Adhesive, and Slit Release Liner, illustrating the patch's composition and function.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.